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Abstract
Background: Drug resistance in Plasmodium falciparum is common in many endemic and other settings but there
is no clear recommendation on when to change therapy when there is delay in parasite clearance after initiation
of therapy in African children.
Methods: The factors contributing to delay in parasite clearance, defined as a clearance time > 2 d, in falciparum
malaria were characterized in 2,752 prospectively studied children treated with anti-malarial drugs between 1996
and 2008.
Results: 1,237 of 2,752 children (45%) had delay in parasite clearance. Overall 211 children (17%) with delay in
clearance subsequently failed therapy and they constituted 72% of those who had drug failure, i.e., 211 of 291
children. The following were independent risk factors for delay in parasite clearance at enrolment: age less than or
equal to 2 years (Adjusted odds ratio [AOR] = 2.13, 95% confidence interval [CI]1.44-3.15, P < 0.0001), presence of
fever (AOR = 1.33, 95% CI = 1.04-1.69, P = 0.019), parasitaemia >50,000/ul (AOR = 2.21, 95% CI = 1.77-2.75,
P < 0.0001), and enrolment before year 2000 (AOR= 1.55, 95% CI = 1.22-1.96, P < 0.0001). Following treatment,
a body temperature ≥ 38°C and parasitaemia > 20000/μl a day after treatment began, were independent risk
factors for delay in clearance. Non-artemisinin monotherapies were associated with delay in clearance and
treatment failures, and in those treated with chloroquine or amodiaquine, with pfmdr 1/pfcrt mutants. Delay in
clearance significantly increased gametocyte carriage (P < 0.0001).
Conclusion: Delay in parasite clearance is multifactorial, is related to drug resistance and treatment failure in
uncomplicated malaria and has implications for malaria control efforts in sub-Saharan Africa.
Background
The emergence and spread of multidrug resistance in
Plasmodium falciparum is a major obstacle to successful
chemotherapeutic control of the disease. Resistance to
chloroquine (CQ) and sulphadoxine-pyrimethamine (SP)
is now widespread in sub-Saharan Africa, South Asia
and South America [1,2] and there is an increased
chance that resistance to mefloquine (MQ), already
widespread in Southeast Asia [3-6], may spread to
Africa. With increasing failure of amodiaquine (AQ) in
areas of intense transmission [7-9] and increasing
selection of P. falciparum multidrug resistance gene 1
(Pfmdr 1) in asexual and sexual parasites following treat-
ment of infections with artemether-lumefantrine (AL)
[10], there is a rising spectre of reduced responses to
artemisinin-based combination therapy (ACT) in Africa.
Despite increasing drug treatment failure, there is no
clear guidelines, at least in Nigeria, about the time to
change anti-malarial drug treatment if parasites do not
clear quickly from peripheral blood following treatment
of uncomplicated acute infections in African children. It
is postulated in the present study that, parasite clearance
exceeding two days is associated with risk of treatment
failure and resistance and could be used as a criterion
to change therapy in very young children. The present
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clearance and anti-malarial treatment failure in
children with falciparum malaria in an area of intense
transmission in south-western Nigeria, where resistance
in P. falciparum to CQ and SP deteriorated steadily
over the past ten years.
Methods
Patients
The studies took place between July 1996 and July 2008
in patients presenting at the University College Hospital
in Ibadan, a hyperendemic area for malaria in south-
western Nigeria [11]. Ethical clearance was provided by
the local ethics committee. During the period, a series
of anti-malarial drug studies were conducted to evaluate
the efficacy and safety of different treatment regimens
(Table 1). Details of the drug efficacy studies have been
described before [12-16].
Briefly, children with symptoms compatible with acute
falciparum malaria who fulfilled the following criteria
were enlisted in the study: age 144 months or below,
mono-infection with P. falciparum, parasitaemia ≥ 2,000
asexual forms/μl blood, negative urine tests for anti-
malarial drugs 4-aminoquinolines and sulphonamides
(Dill-Glazko and lignin tests, respectively), absence of
concomitant illness, no evidence of severe malaria [17],
and written informed consent given by parents or guar-
dians. After enrolment and start of treatment (day 0),
follow-up with clinical and parasitological evaluation
was at days 1-7, and then on days 14 - 28 up to 2004.
After 2004, follow-up was for 42 d. Clinical evaluation
consisted of a general clinical examination including
measurement of weight, core temperature and physical
examination.
Assessment of parasitaemia
Thick and thin blood films prepared from a finger prick
were Giemsa-stained and were examined by light micro-
scopy under an oil-immersion objective, at × 1,000 mag-
nification, by two independent assessors. Parasitaemia in
thick films was estimated by counting asexual parasites
relative to 1,000 leukocytes, or 500 asexual forms,
whichever occurred first. From this figure, the parasite
density was calculated assuming a leukocyte count of
6,000/μl of blood. Gametocytes were also counted in
thick blood films against 1,000 leukocytes assuming an
average leukocyte count of 6,000/μl of blood [18-20].
Haematocrit was done at enrolment in 994 of the
Table 1 Treatment regimens and time of study in the children enrolled
Drugs* Regimens† No of patients Year
AQ 30 mg/kg of amodiaquine base over 3 days, that is, 10 mg/kg daily 573 2000-2006
AQAS Artesunate given as 4 mg/kg dail for 3 d plus amodiaquine given as in AQ above 142 2004-2005
AQPS Amodiaquine given as in AQ above plus sulphadoxine-pyrimethamine given as 25 mg/kg
of the sulphadoxine component at presentation
69 2000
AQSP Amodiaquine given as in AQ above plus sulphalene-pyrimethamine given as 25 mg/kg
of the sulphalene component at presentation
91 2006
AMQ Mefloquine given as 25 mg/kg at presentation plus artesunate as given in AQAS above 174 2007-2008
AL Artemether (20 mg) plus lumefantrine (120 mg) given thus: 5-14 kg received 1 tab.,
15-24 kg received 2 tab., 25-34 kg received 3 tab., > 34 kg received4 tab.
at presentation, 8 h later and at 24, 36, 48 and 60 h after first dose
90 2006
AS Artesunate given as 28 mg/kg over 7 days, that is, 4 mg/kg daily 120 2006
COT Co-trimoxazole given as 20 mg of the sulphamethoxazole component twice daily 104 1998-1999
CQ 30 mg/kg of chloroquine base over 3 days, that is, 10 mg/kg daily 388 1996-2004
CQCP 30 mg/kg of chloroquine base over 3 days, that is, 10 mg/kg daily plus chlorpheniramine 8 mg
start and 4 mg 8 hourly for 5 d.
315 1996-1999
CQKET 30 mg/kg of CQ base over 3 days, i.e., 10 mg/kg daily plus ketotifen 25 mg/kg statim,
followed by 0.125 mg/kg 8 hourly for 4 d.
70 2001
CQPS 30 mg/kg of amodiaquine base over 3 days, that is, 10 mg/kg daily plus sulphadoxine-pyrimethamine
given as 25 mg/kg of the sulphadoxine component at presentation
107 2000/2004
MQ Mefloquine given as 25 mg/kg at presentation 176 2007-2008
SP Pyrimethamine-sulphadoxine given as 25 mg/kg of the sulphadoxine component at presentation 291 1996-2004
SPP Sulphadoxine-pyrimethamine given as in PS above plus probenecid at 20-25 mg/kg in two divided
doses daily for 3 day
42 2004
† All drugs were administered orally. AQ, amodiaquine; AQART, amodiaquine plus artesunate; AQPS, amodiaquine plus pyrimethamine-sulphadoxine; AQSP,
amodiaquine-sulphalene-pyrimethamine; ARTMF, mefloquine plus artesunate; ARTMLUM, artemether plus lumefantrine; AS, artesunate; COT, cotrimoxazole; CQ,
chloroquine; CQCP, chloroquine plus chlorpheniramine; CQKET, chloroquine plus ketotifine; CQPS, chloroquine plus pyrimethamine-sulphadoxine; MQ,
mefloquine; PS, pyrimethamine-sulphadoxine; PSP, pyrimethamine-sulphadoxine plus probenecid;
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apy (NACT) or ACT in order to evaluate the safety of
combination anti-malarial therapies.
Evaluation of response to drug treatment
Response to drug treatment was assessed using World
Health Organization (WHO) criteria [21] as follows: S =
sensitive, clearance of parasitaemia without recurrence;
RI (mild resistance) = parasitaemia disappears but reap-
pears within 7 to 14 days; RII (moderate resistance) =
decrease of parasitaemia but no complete clearance
from peripheral blood; RIII (severe resistance) = no pro-
nounced decrease or increase in parasitaemia at 48
hours after treatment. In those with sensitive or RI
response, parasite clearance time (PCT) was defined as
the time elapsing from drug administration until there
was no patent parasitaemia for at least 72 h. Delay in
parasite clearance was defined as a parasite clearance
time > 2 d, and was based on the asexual life cycle of 48
h in the infected erythrocyte [22]. The above criteria
used for assessing responses to anti-malarials were used
in order to maintain uniformity and because they were
the recommended criteria when studies started.
Molecular analysis of pfmdr 1 and pfcrt
At enrolment, 100 μl of capillary blood was collected on
to 3 MM Whatman™ filter paper for resistance markers
determination in 2000 and 2006 in those treated with
CQ or AQ. Pfmdr 1 and pfcrt genotypes were assessed
by PCR using methods described previously [7,10]. Sin-
gle nucleotide polymorphisms in pfmdr 1 and pfcrt were
detected by nested PCR-RFLP methods.
Statistical analysis
Data were analysed using version 6 of the Epi-Info soft-
ware [23], and the statistical program SPSS for Windows
version 10.01 [24]. Proportions were compared by calcu-
lating c
2 with Yates’ correction. Normally distributed,
continuous data were compared by Student’s t-tests and
analysis of variance (ANOVA). Data not conforming to
a normal distribution were compared by the Mann-
Whitney U-test and the Kruskal-Wallis test (or by Wil-
coxon rank sum test). A multiple logistic regression
model was used to test the association between parasite
clearance > 2 d (yes or no at presentation or during fol-
low up) and factors that were significant at univariate
analysis: age, presence of fever, asexual parasitaemia at
presentation or during follow-up, a history of vomiting,
and drug treatment. Because the study was conducted
over a period of 12 years, time in years since the com-
mencement of trials was included as a covariate in the
model for pretreatment delay in parasite clearance. P-
values of < 0.05 were taken to indicate significant
differences.
Results
Between July 1996 and July 2008, 2,752 children (1342
females) were enrolled into the drug studies. All were
recruited into prospective randomized studies and all had
primary infections with P. falciparum. There were 1,716
under five-year olds. The geometric mean parasitaemia
at enrolment was 34,044/μl (95% CI 30,400 - 33,664)
(Table 2). Follow up was achieved in 2,562 children for
up to 21 days and in 2,122 children for 28 or 42 days.
Treatment failures
Overall 57 of the 2,752 children (2.1%) had treatment
failure by day 7, and this rose to 113/2,695 (4.2%) by
day 14, and 62/796 (7.8%) by day 21 (c
2 for trend =
155.8, P < 0.0001).
Drug treatment and delay in parasite clearance
Overall, delay in parasite clearance occurred in 1237 of
the 2752 children (45%) (Figure 1). The highest propor-
tions of children showing delay in parasite clearance
were found in those treated with CQ (70.8%), PS
(63.9%), CQCP (60%), COT (58.6%) AQ (52%) CQKET
(51.4%) CQPS (42%), AQPS (37.6%), AQSP (37.3%), PSP
(30.9%), and MQ (22.7%). The proportions of children
with delay in parasite clearance were significantly lower
in those treated with AS (2.5%), AQAS (9.9%), AL
(6.6%) and, AMQ (5.7%) when compared with the latter
group above (c
2 = 447.91, P < 0.0001). There was no
significant difference in the proportions of children with
delay in clearance in those treated with AS (3 of 120),
AQAS (14 of 142), AL (6 of 90), and AMQ (10 of 174)
Table 2 Baseline clinical and parasitological parameters
of the 2752 children enrolled in the study
Variables Mean ± SD
(range)
95% CI
Age (year) 6.1 ± 3.0 (0.5-12) 6.0-6.2
No. < 5 years 1716 (63%)
Weight (kg) 17.3 ± 6.4 (5-47) 17.0-17.6
Axillary temperature (°C) (n = 2428) 38.3 ± 1.2 (34-42) 38.2-38.3
No. with > 40°C 210
Haematocrit (%) (n = 994) 30.5 ± 4.8 (10-51) 30.1-30.7
No. with < 30% 380
Parasitaemia (/μl)
GM 34,044 30,400-33,664
Range 2009-1,194,285
No with > 100,000 (/μl) 638 (23.2%)
No. with >250,000 (/μl) 187 (6.8%)
Gametocytaemia (/μl) GM 27 (6 - 4188)
Duration of illness (d) 3.0 ± 1.4 (1-14) 2.9-3.0
Duration of vomiting (d) 1.3 ± 1.4 (1-9) 1.2-1.3
GM, geometric mean
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2 = 6.1, df = 3, P = 0.10). The addition of AS to MQ
(AMQ) significantly reduced the proportion of patients
with delay in clearance (40 of 176 for MQ v 10 of 174
for AMQ, c
2 = 19.24, P = 0.0001). Similarly, the addi-
tion of AS to AQ (AQAS) significantly reduced the pro-
portion of patients with delay in clearance (298 of 573
for AQ v 14 of 142 for AQAS, c
2 = 80.49, P < 0.0001).
Temporal changes in parasite clearance time and
proportion of children with delay in clearance in those
treated with chloroquine, sulphadoxine-pyrimethamine
and amodiaquine
The changes in parasite clearance times (PCT) and the
proportions of children with delay in clearance between
1996 and 2004, or between 2000 and 2006, in patients
treated with CQ (n = 316), SP (n = 218), or AQ (n = 573)
were evaluated. There was a significant increase in PCT
from 3.08 ± 1.06 d (n = 53) in 1996 to 4.23 ± 2.08 d (n =
76) in 2004 (P < 0.0001), but there was no difference in
proportion with delay in parasite clearance during the
same period (71.7% in 1996 and 80.2% in 2004, c
2 for
trend = 1.36, P = 0.24) in those treated with CQ (Figure 2).
There was a significant increase in PCT from 3.19 ±
1.72 d (n = 48) in 1996 to 4.21 ± 1.84 d (n = 71) in
2004 (P = 0.0001) and a significant increase in propor-
tion with delay in parasite clearance during the same
period (58.3% in 1996 and 80.3% in 2004, c
2 for trend =
5.99, P = 0.014) in those treated with SP (Figure 2).
Figure 1 Numbers of children with delay in parasite clearance (> 2 d) following treatment with antimalarial drugs. Total enrolled (Green
line), No. with parasite clearance > 2 d (Red line), No. with parasite clearance > 2 d who proceded to failure (Blue line). [see Table 1 for
antimalarial drug abbreviations].
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± 0.80 d (n = 104) in 2000 to 2.87 ± 1.39 d (n = 118) in
2006 (P = 0.0001), but there was no difference in pro-
portion with delay in parasite clearance during the same
period (53% in 2000 and 59% in 2006, c
2 for trend =
0.81, P = 0.36) in those treated with AQ (Figure 2).
Risk factors for delay in parasite clearance at enrolment
The following were found to be independent risk factors
for delay in parasite clearance at enrolment (Table 3):
age ≤ 2 years (Adjusted odds ratio [AOR] = 2.13, 95%
confidence interval [CI] = 1.44-3.15, P < 0.0001), pre-
sence of fever (AOR = 1.33, 95% CI = 1.04-1.69, P =
0.019), parasitaemia >50,000/μl (AOR = 2.21, 95% CI =
1.77-2.75, P < 0.0001), and enrolment before year 2000
(AOR = 1.55, 95% CI = 1.22-1.96, P < 0.0001). A history
of vomiting was associated with an increased risk of
delay in clearance (crude odds ratio = 1.34, 95% CI =
1.07 -1.58, P = 0.009).
Risk factors for delay in parasite clearance following
initiation of treatment
Following treatment, a body temperature ≥ 38°C and
parasitaemia > 20,000/μl blood a day after treatment
began, were independent risk factors for delay in clear-
ance (Table 4). Non-artemisinin monotherapy was asso-
ciated with delay in clearance.
Delay in parasite clearance and treatment failure
Of the 20, 146, 10, 15, 19, and 62 children who failed
t r e a t m e n tw i t hA Q ,C Q ,C O T ,C Q C P ,M Q ,a n dP S ,
respectively, 13, 119, 7, 14, 5, and 50 children, respec-
tively were those who previously had delay in parasite
clearance (Figure 3). Overall, 291 children failed treat-
ment. Of these, 211 (72%) had delay in parasite clear-
ance. The latter represent 17% of the total children
(1237) with delay in parasite clearance. Thus delay in
clearance may be related to subsequent drug treatment
failure.
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Figure 2 Temporal changes in parasite clearance time (PCT) and proportion with delay in parasite clearance (PC > 2 d) in children
treated with amodiaquine (AQ), chloroquine (CQ) or pyrimethamine sulphadoxine (PS) between 1996 and 2006. [Proportion of children
treated with AQ who had PC > 2 d (Black line), Proportion of children treated with CQ who had PC > 2 d (X), Proportion of children treated
with PS who had PC > 2 d (O), PCT for AQ treated children (–￿–), PCT for CQ treated children (Blue line), PCT for PS treated children (+)]. Bars
represent standard deviation.
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Overall 10% (282/2,752) of the children had patent
gametocytaemia on presentation. In those treated with
CQ gametocyte carriage at enrolment did not increase
from 1996 (26%, 14/53) to 2003 (22% 14/62), c
2 for
trend = 0.417, P = 0.23. Similarly, in those treated with
SP, gametocyte carriage at enrolment did not increase
from 1996 (22%, 11/48) to 2003 (20% 15/72), c
2 for
trend = 0.075, P = 0.78. In those treated with AQ
gametocyte carriage at enrolment also did not increase
from 2000 (11.5%, 12/104) to 2006 (13% 16/120), c
2 for
trend = 0.55, P = 0.46.
The majority of children without gametocytaemia at
enrolment, who later developed gametocytaemia did so
on day 7 (36%, 156/433). In those who did not carry
gametocyte at enrolment, gametocyte carriage within
Table 3 Predictors of delay in parasite clearance at presentation in children with acute falciparum malaria
Variables Number enrolled PC
>2 d
Crude OR
(95% CI)
P
Value
Adjusted OR (95% CI) P
Value
Age (years)
>2 2446 1076 1 1
≤ 2 267 140 1.40 (1.09 -1.80) 0.008 2.13 (1.44 -3.15) <0.0001
Gender
Female 1342 607 1
Male 1240 557 0.98 (0.84 -1.15) 0.870 - -
Fever*
Absent 686 252 1 1
Present 1743 842 1.6 (1.34 -1.93) <0.0001 1.33 (1.04-1.69) 0.019
Duration of illness (d)
≤ 3 2085 926 1
> 3 521 246 1.12 (0.90 - 1.30) 0.225 - -
Haematocrit (%)
≥ 30 614 182 1
<30 380 114 1.01 (0.76 - 1.34) 0.904 - -
Parasitaemia (/μl blood)
≤ 50,000 1607 634 1 1
> 50,000 1145 603 1.70 (1.46 -1.99) <0.0001 2.21 (1.77 - 2.75) < 0.0001
Gametocytaemia
Absent 2086 896 1
Present 232 90 0.84 (0.63 - 1.10) 0.224 - -
Vomiting
No 1005 519 1 1
Yes 665 387 1.34 (1.07-1.58) 0.009 1.21 (0.90-1.51) 0.089
Hepatomegaly
Absent 471 237 1
Present 798 430 1.54 (0.91 - 1.44) 0.219 - -
Year of enrolment
2000 onward 2165 872 1 1
Before or 1999 587 365 2.43 (2.02 - 2.94) 0.0.00 1.55 (1.22-1.96) < 0.0001
CI, confidence interval; OR, odd ratio; PC, parasite clearance, *Body temperature ≥ 37.5°C
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site clearance time; it rose from 13% (188/1,374) among
children who cleared their parasitaemia on day 1 or on
day 2 to 24.5% (245/1,000) among those who cleared
their parasitaemia on day 3 or on day 4 (c
2 = 44.69,
P < 0.0001) (Figure 4).
Pfmdr 1 and pfcrt findings
A total of 260 isolates from 260 children were selected
for genetic analysis of pfmdr1/pfcrt of which 256 were
successfully determined. None of the 260 children was
aged ≤ 2 years, but 137 children were aged 3 to < 5
years. Infections were classified as mutant for pfmdr 1/
pfcrt,m i x e d ,o rw i l dt y p e .T h ep r e v a l e n c eo ft h et h r e e
categories were 51% (70/139), 36% (51/139) and 13%
(15/139), respectively in 2000. In 2006, the correspond-
ing prevalence was 50% (59/118), 36% (42/118) and 14%
(17/118). In the 256 children, 13% (18/129), 4% (4/93),
and 5% (2/34) with mutant, mixed, and wild alleles,
respectively were treatment failures. The difference
between these proportions was significant (c
2 =6 . 4 9 ,d f
= 2, P = 0.039). The proportions of 3 to < 5 year-olds
with parasite clearance > 2 d in these groups were: 75%
(48/64), 51% (28/54) and 63% (12/19), respectively for
mutants, mixed and wild type. The difference in
these proportions was significant (c
2 =6 . 8 4 ,d f=2 ,
P = 0.032).
Discussion
The emergence of drug resistance in P. falciparum,i n
particular to CQ and SP, in south-western Nigeria has
been relatively slow but steady [12-14,25,26]. The aetiol-
ogy of the treatment failure in children from this ende-
mic area has been multifactorial including the selection
of Pfmdr-1 gene following anti-malarial treatment [7,10].
The overall parasitological failure rate of over 40% with
CQ and SP [25,26] clearly warrants discontinuing the
use of these drugs as monotherapies or their inclusion
as part of combination therapies. Thus, the recom-
mended continuing use of SP in intermittent preventive
therapy in pregnancy in this endemic area [27] should
have little or no impact because of widespread clinical
and molecular markers of resistance to this drug [28].
The latter is supported by a recent study (Gbotosho &
Happi, personal communication), showing lack of pro-
tective value of SP in intermittent preventive therapy of
malaria in a group of pregnant women in this endemic
area.
Table 4 Predictors of delay in parasite clearance on day 1 after treatment in children with acute falciparum malaria
Variables Number enrolled PC
>2 d
Crude OR
(95% CI)
P
Value
Adjusted OR (95% CI) P
Value
Axillary temperature (°C)
<38.0 2326 1012 1 1
≥ 38.0 228 139 2.02 (1.53 -2.67) <0.0001 1.80 (1.30-2.50) < 0.001
Parasitaemia (/μl blood)
≤ 20,000 1328 463 1 1
>20,000 683 467 5.25 (4.20 - 6.48) <0.0001 5.13 (4.14 - 6.35) < 0.001
Drug treatment *
CQ 388 275 1 1 1
AQ 573 298 0.44 (0.33 - 0.58) <0.0001 0.79 (0.63 - 0.98) < 0.03
AQAS 142 14 0.05 (0.03 - 0.08) <0.0001 0.24 (0.10 - 0.57) < 0.0001
AQPS 69 26 0.24 (0.14 - 0.42) <0.0001 0.44 (0.26 - 0.73) 0.002
AQSP 91 34 0.25 (0.15 - 0.39) <0.0001 0.43 (0.29 - 0.68) < 0.0001
AMQ 174 10 0.03 (0.01 - 0.05) <0.0001 0.04 (0.02 - 0.09) < 0.0001
AL 90 6 0.03 (0.01 - 0.07) <0.0001 0.05 (0.02 - 0.12) < 0.0001
AS 120 3 0.01 (0.00 - 0.03) <0.0001 0.02 (0.00 - 0.06) < 0.0001
COT 104 61 0.58 (0.37 - 0.91) 0.017 1.03 (0.68 - 1.36) 0.877
CQCP 315 189 0.61 (0.45 - 0.84) 0.002 1.09 (0.83 - 1.42) 0.512
CQKET 70 36 0.43 (0.25 - 0.73) 0.001 0.77 (0.47 - 1.25) 0.029
CQPS 107 46 0.31 (0.19 - 0.48) <0.0001 0.54 (0.36 - 0.82) 0.004
MQ 176 40 0.12 (0.08 - 0.18) <0.0001 0.21 (0.15 - 0.31) < 0.0001
SP 291 186 0.72 (0.52 - 1.00) 0.055 - -
SPP 42 13 0.18 (0.09 - 0.37) <0.0001 0.33 (0.17 -0.98) 0.001
CI, confidence interval; OR, odd ratio; PC, parasite clearance
* Values of OR represent chances of delay in parasite clearance
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Page 7 of 11Figure 3 Treatment failures following antimalarial drugs in children. Total failure (Red triangle), children who previously had delay in
parasite clearance (Blue triangle).
Figure 4 Relationship between parasite clearance and gametocyte carriage.
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nity levels are difficult to manage and early identification
and prompt treatment of patients at risk of subsequent
treatment failure would improve patient care and com-
munity management of resistant infections. In the pre-
sent study, a systematic evaluation of the pre-treatment
and during-treatment factors contributing to delay in
parasite clearance, the relationship between delay in
parasite clearance and treatment failure, and effects of
non-artemisinin and artemisinin mono- or combination
therapy on parasite clearance in children were done.
The results showed that delay in parasite clearance is
multifactorial in origin with the host, parasite and drug
factors contributing almost equally to delay in clearance
and subsequent failure of treatment in those with delay
in parasite clearance.
The age-and pretreatment parasite population size-
dependent delay in parasite clearance are likely linked to
treatment outcome by affecting both the immune-
dependent ability to clear and the probability of survival
of a subpopulation of asexual blood parasite stages,
respectively. In cases of polyclonal infections, a common
finding in this endemic area [7,29,30], this subpopula-
tion may likely comprise drug-insensitive parasites
[22,31,32]. Thus, these two phenomena are reminiscent
of the age- and parasite density-dependent risks of treat-
ment failure for many anti-malarial drugs
[3,5,25,26,33,34]. Therefore, it would appear delay in
parasite clearance is an intermediate step in the progres-
sion from drug-sensitive to drug insensitive outcome for
many anti-malarials. This should be so because in
uncomplicated malaria infections, there is less inhibition
of parasite multiplication by unbound anti-malarial drug
levels as resistance increases [31].
Interestingly, pre-treatment and intra-treatment ele-
vated body temperatures were independent risk factors
for delay in clearance. Fever is considered a crude mea-
sure of unspecific immune responsiveness [35]. If the
findings are not due to chance, the presence of elevated
body temperature a day after treatment began, coupled
with a high parasite density should be sensitive clinical
indicators of delay in response to anti-malarial drugs.
Indeed, high parasite density on day 1 is a very sensitive
indicator of delay in parasite clearance (Table 4). Again,
these are reminiscent of the indicators of the risk factors
for treatment failure for many anti-malarial drugs.
In general, progressive and significant elongations in
parasite clearance times over time were striking features
of treatment outcomes in children treated with CQ, and
S P ,t h et w om o s tw i d e l ya n dl o n g e s tu s e dd r u g si n
south-western Nigeria, and for AQ, a drug that is less
frequently used, but is a partner drug for artesunate.
These elongations were not accompanied by significant
increases in proportions of patients with delay in
parasite clearance during the same periods in those trea-
ted with CQ and AQ, suggesting similar mechanism(s)
for development of resistance in the parasite to both
drugs. In addition, the absence of increase in proportion
with delay in clearance over time could have been due
to the fact that these proportions were already above
50% when the studies began in 1996 and 2000, respec-
tively for CQ and AQ. This would suggest that the 50%
threshold may be the time to consider change in treat-
ment policy at the community or national level in this
endemic area.
Non-artemisinin monotherapy and non-artemisinin
combination therapy were associated with significantly
increased proportions of children with delay in clear-
ance. These findings call for a new strategy to determine
the maximum point in time at which to effect change in
therapy in policy formulation with the widespread use
of ACT in Africa. Perhaps this time point may be when
50% of a population of under-three to under-five year
olds show delay in parasite clearance. This is best exem-
plified by the results from the children treated with
amodiaquine, where over 50% showed a delay in clear-
ance and 65% of those who were treatment failures were
those with demonstrable delay in clearance. These find-
ings contrast sharply with those found in children trea-
ted with artesunate and artemisinin-based combination
therapy and strongly support the WHO recommenda-
tion of ACT [1] as first line treatment globally. How-
ever, it is likely that with increasing use of ACT on the
African continent, significant increases in the proportion
of children with delay in parasite clearance will be seen
within a decade as has recently been demonstrated for
artesunate-mefloquine use in north-western Thailand
[36].
Delay in parasite clearance was associated with
increased gametocyte carriage and, therefore, presum-
ably with a potential for increased transmissibility of
drug resistant phenotype. This is of public health import
since delay in parasite clearance, by virtually all anti-
malarial drugs, including ACT, is associated with an
increased risk of gametocytaemia [36-38].
Over the study period the prevalence of pfmdr1/pfcrt
mutants and mixed mutants/wild was above 50%, and
with little or no increase between 2000 and 2006. Intri-
guingly, this was associated with increase in parasite
clearance time in CQ and AQ-treated patients. Carriage
of mutant parasites was associated with an increased
risk of treatment failure. Additionally, the proportions of
under five-year-olds with delay in parasite clearance
increased with genotype classification suggesting that
delay in parasite clearance was associated with drug
resistance and treatment failure in young children. How-
ever, there are other factors that may affect susceptibility
that were not evaluated in these children.
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ance used in this study: one asexual cycle of the blood
stage infection takes approximately 48 h. Thus after two
days, the parasites appearing in blood and visible by
microscopy when the patient presents, should be the
one to appear in blood 48 h after treatment began if the
drug does not kill all the parasites [31]. Thus the use of
delay in clearance, in the opposite, and in a more practi-
cal way, is analogous to the parasite reduction ratio [22],
but with an inclination for easy applicability and opera-
tional research.
Conclusion
A better understanding of the multifactorial causes and
mechanisms of delay in parasite clearance following
anti-malarial treatment regimens can provide vital infor-
mation for setting policy recommendations at case man-
agement, community, and national levels and prolonging
the clinical life of the currently useful anti-malarials.
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